IDEAYA Biosciences Files 8-K on Financials
Ticker: IDYA · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
IDEAYA filed an 8-K on Feb 13, 2025, covering financials. No major news yet.
AI Summary
On February 13, 2025, IDEAYA Biosciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text, but the filing indicates a standard reporting event.
Why It Matters
This filing provides investors with updated information regarding IDEAYA Biosciences' financial health and operational status, which is crucial for investment decisions.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for financial condition and does not appear to contain any immediately alarming or significant new information.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- February 13, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for IDEAYA Biosciences, Inc.?
The primary purpose of this 8-K filing is to report on IDEAYA Biosciences, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of February 13, 2025.
What is IDEAYA Biosciences, Inc.'s state of incorporation and IRS Employer Identification Number?
IDEAYA Biosciences, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 47-4268251.
What is the principal executive office address for IDEAYA Biosciences, Inc.?
The principal executive office address is 5000 Shoreline Court, Suite 300, South San Francisco, California 94080.
Does this filing indicate any specific new developments or material events for IDEAYA Biosciences, Inc.?
The provided text of the filing indicates it is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering results of operations and financial condition, but does not detail specific new developments or material events within the excerpt.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-02-13 06:05:08
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- idya-20250213.htm (8-K) — 48KB
- idya-ex99_1.htm (EX-99.1) — 181KB
- img107722786_0.jpg (GRAPHIC) — 7KB
- 0000950170-25-019314.txt ( ) — 370KB
- idya-20250213.xsd (EX-101.SCH) — 28KB
- idya-20250213_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, IDEAYA Biosciences, Inc. (the "Company") announced its financial results for the fourth quarter and full year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: February 13, 2025 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer